MARTIN JOHN C 4
4 · Kronos Bio, Inc. · Filed Oct 16, 2020
Insider Transaction Report
Form 4
Kronos Bio, Inc.KRON
MARTIN JOHN C
Director
Transactions
- Conversion
Convertible Promissory Note
2020-10-14→ 0 total(indirect: See footnote)Exercise: $16.15Exp: 2022-02-20→ Common Stock (205,260 underlying) - Conversion
Common Stock
2020-10-14+914,333→ 914,333 total(indirect: See footnote) - Conversion
Common Stock
2020-10-14+756,971→ 1,671,304 total(indirect: See footnote) - Purchase
Common Stock
2020-10-14$19.00/sh+75,800$1,440,200→ 1,952,364 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2020-10-14−717,509→ 0 total(indirect: See footnote)→ Common Stock (756,971 underlying) - Conversion
Common Stock
2020-10-14$16.15/sh+205,260$3,314,949→ 1,876,564 total(indirect: See footnote) - Conversion
Series Seed Preferred Stock
2020-10-14−866,667→ 0 total(indirect: See footnote)→ Common Stock (914,333 underlying)
Footnotes (3)
- [F1]Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
- [F2]The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
- [F3]The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering.